Are AstraZeneca shares worth buying?

AstraZeneca shares have a high price-to-earnings ratio, but I don’t think you should let that put you off this FTSE 100 (INDEXFTSE:UKX) stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the stock market crash in March, investors have become wary of which shares to buy. This has resulted in some sectors being avoided and others seeing high demand. Unloved sectors include travel, hospitality, oil and finance, while loved sectors include technology and pharmaceuticals. This has led to a lot of high-quality shares with ridiculously high price-to-earnings ratios (P/E). Think AstraZeneca (LSE:AZN) with its earnings multiple of 104, Avon Rubber at 86 and Games Workshop at 45.

As I consider buying these shares, I worry if a market correction occurs, I’ll have paid too much at a price point that’s unsustainable. This problem is not unique to the UK, it’s even more prevalent in the US, where Tesla has reached an astronomical P/E of 959.

A high P/E should signal quality

However, successful British fund manager Terry Smith recently said that a high P/E will not necessarily lead to future disappointment. This is because many companies doing well today previously had a high P/E and it would have been a mistake to avoid them for that reason alone. When a company looks strong and offers consumers and shareholders value, it could continue to do so.

A price-to-earnings ratio is calculated by dividing the current stock price by its earnings-per-share (EPS). When a company’s earnings increase, then the P/E will usually reduce. 

The reason a company achieves a high P/E in the first place is because a deluge of investors buying it drives its share price up. If that many people believe in the stock, then surely this should signal a quality company? I think that’s what’s happened in AstraZeneca’s case.

Is the AstraZeneca share price too expensive?

The AstraZeneca share price has skyrocketed this year as it gets set to battle Covid-19 via its vaccine collaboration with Oxford University. AstraZeneca has a fantastic array of medicines already available and many more in the pipeline. It provides diversification through its variety of treatment types, and is enjoying product sales growth. It also offers a dividend yield of 2.5%, which may tempt long-term investors looking to add dividend stocks to their portfolios.

The trouble with pharma companies is they’re up against several factors, not least being a competitive marketplace. The economic backdrop can significantly influence share price volatility. And there’s always the risk of failed trials, adverse reactions to drugs and massive costs in research and development. Last week AstraZeneca halted its Covid-19 vaccine trial to investigate a bad reaction in one of its participants. The trial has now resumed, but it highlights the risks involved when dealing with people’s health.

AstraZeneca’s R&D department is world leading and advances in technology are helping it break down barriers. It’s pumping a lot of money into R&D, which stands to pay off handsomely if it results in ground-breaking medicines to tackle the world’s worst health problems.

AstraZeneca shares have high price-to-earnings ratio
Source: AstraZeneca – New Cambridge R&D Centre and Global HQ

So, are AstraZeneca shares worth buying? I think for the long term they probably are. I do think they’re expensive today, but risk aside, it’s an excellent company. If you really believe in a business and like everything it offers, I don’t think you should let its high price-to-earnings ratio put you off. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Would a stock market crash matter?

Christopher Ruane explains why a stock market crash could turn out to be positive, not negative, for a private investor…

Read more »

Investing Articles

Has the Rolls-Royce share price peaked?

After a strong 2023 performance and (so far) in 2024, the Rolls-Royce share price has stuttered in recent days. Christopher…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Turning a £20k ISA into a £13,900 yearly second income? It’s possible!

By investing a £20k ISA now using certain basic principles, our writer thinks he could set up a second income…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With no savings, I’d follow Warren Buffett’s number one rule to build wealth

Can this one piece of Warren Buffett wisdom really help our writer as he aims to build wealth in the…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

A second income of £1k a month from just £10 a day! How would I do that?

Mark David Hartley considers how to build a second income stream starting from just £10 a day. Is £1,000 a…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Turn £8,900 into a £24k annual passive income? Here’s how!

Christopher Ruane applies some investing lessons from billionaire Warren Buffett when explaining how he'd aim to earn sizeable passive income…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

7%+ dividend yields! 4 FTSE 100 shares for investors to consider buying in April

These FTSE shares offer dividend yields comfortably above the index average of 3.7%. Here's why they could be good passive…

Read more »

Dividend Shares

£10k in an ISA? Here’s how to generate a ton of passive income

Passive income can provide a lot more financial freedom and security. Here’s an easy way to generate some within an…

Read more »